Inclusion Criteria

DISEASE CHARACTERISTICS:

- Histologically or cytologically proven diagnosis of a malignant disease for which no
satisfactory treatment exists at the time of enrollment

- Patients with brain metastases that, at the time of study enrollment, are controlled
and do not require treatment with corticosteroids are eligible

PATIENT CHARACTERISTICS:

- WHO performance status 0-2

- Life expectancy ≥ 3 months

- ANC > 1.5 x 10^9/L

- Platelet count > 100 x 10^9/L

- Creatinine clearance > 50 mL/min

- Serum bilirubin < 1.5 mg/dL

- AST or ALT < 2.0 times upper limit of normal (unless clearly due to the presence of
tumor)

- Not pregnant or nursing

- Fertile patients must use effective contraception

- Patient must be capable of understanding the nature of the trial and must give
written informed consent

- No unstable or severe intercurrent medical conditions or active, uncontrolled
infection

- No history of allergic reactions to nonsteroidal anti-inflammatory drugs

- No bleeding peptic ulcer within the past 3 months

- No allergy to sulfa drugs

PRIOR CONCURRENT THERAPY:

- Recovered from all prior therapy

- No radiotherapy or chemotherapy within the 3 weeks (nitrosoureas or mitomycin C
within 6 weeks) prior to anticipated first day of dosing

- No concurrent therapy with other investigational agents or antineoplastic therapy